TQ Quiz | Candid Conversations: Ocular Surface Disease (Scottsdale 2025) by Events@optometricedu.com | Jan 26, 2025 | 2025 Scottsdale, TQ Courses | 0 comments "*" indicates required fields This field is hidden when viewing the formDate (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent 60 days past date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date Difference (Hidden)1. There are approximately _________ patients with dry eye disease (DED) in the United States, yet half are undiagnosed.* A. 10 Million B. 20 Million C. 30 Million D. 40 Million 2. What is the highest score possible on the Standardized Patient Evaluation of Eye Dryness (SPEED) questionnaire?* A. 8 B. 18 C. 28 D. 38 3. According to Yu et al., what is the average annual cost of managing a dry eye patient from a payer’s perspective?* A. $383 B. $583 C. $683 D. $783 4. All of the following are included in the TFOS DEWS II definition of dry eye except:* A. Hypertonicity B. Hyperosmolarity C. Inflammation D. Neurosensory abnormalities 5. According to Machalińska A, et al., what percentage of contact lens wearers have MGD?* A. 30% B. 40% C. 50% D. 60% 6. Using corneal topography, all of the following signs can be used to detect ocular surface disease except?* A. Hot spots B. Irregular placido rings C. K measurements D. Angle kappa 7. Which ocular surface biomarker or diagnostic test has the highest positive predictive value?* A. Schirmers B. MMP-9 C. Tear osmolarity D. Tear film break up time 8. According to Epitropolous et al, increased _______ can lead to errors in IOL calculations.* A. Osmolarity B. Schirmers C. MMP-9 D. Meibography 9. All of the following are indications for Epi-Mapping except _____________?* A. Refractive Surgery B. Keratoconus C. Dry Eye Disease D. Fuchs Corneal Dystrophy 10. Which of the following is NOT a point of care test used for dry eye disease?* A. Dynamic meibomian gland imaging B. Corneal topography C. Anterior segment optical coherence tomography D. Sjogren biomarker test 11. How many milligrams of EPA/DHA were used in the dream study?* A. 1,000mg B. 2,000mg C. 3,000mg D. 4,000mg 12. Oral medications utilized for the treatment of dry eyes include all of the following except:* A. Prednisone B. Pilocarpine C. Doxycycline D. Omega 3 Fatty Acids 13. According to the Mackie classification for neurotrophic keratitis, Stage II is defined as:* A. Characterized by hyperplasia and/or irregularity of the epithelium, evolving to punctate keratopathy, corneal edema, neovascularization, and stromal scarring. B. Defined by a recurrent or persistent epithelial defects or a PED without stromal thinning C. Stromal involvement leads to corneal ulcer, melting and perforation D. Mild persistent epithelial erosions 14. __________ nervous system is a critical regulator of the lacrimal functional unit and a healthy tear film.* A. Parasympathetic nervous system B. Sympathetic nervous system C. Central nervous system D. Peripheral nervous system 15. What percent of basal tear production is due to inhaled air through the nasal passage?* A. 24% B. 34% C. 44% D. 54% 16. Amniotic membranes have all of the properties except?* A. Anti-inflammatory B. Anti-angiogenic C. Anti-scarring D. Anti-pyretic 17. Dry eye procedures currently represent _____% of all US dry eye revenue?* A. 4% B. 8% C. 14% D. 18% 18. What wavelength of light is used Intense Pulse Light treatments?* A. X-ray B. Gamma rays C. Visible / infrared D. Radiofrequency 19. Which of the following investigational agents for treating MGD targets the eradication of Demodex mites as its mechanism of action?* A. AZR-MD-001 B. NOV03 C. Reproxolap D. TP-03 20. Which was a primary efficacy finding of the phase 2 SEECASE study of NOV03 in patients with DED?* A. Significant improvement in change of total corneal fluorescein staining (tCFS) score B. Trend toward improvement in meibomian gland yielding liquid secretion C. Reduction in collarettes D. Trend toward improvement in patient-reported symptoms Personal InformationName* First Last Email* Phone*OE Tracker #License #Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional CodeScottsdale 2025 - Candid Conversations: Ocular Surface Disease*After 90 days, pricing will increase to $30. Price: (Past 90 Days) Scottsdale 2025 - Candid Conversations: Ocular Surface DiseaseThis course was presented over 90 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: Promotional Discount Price: (Past 60 Days) Retake Discount Price: (Past 60 Days) Promotional Discount Price: Credit Card* This field is hidden when viewing the formCourse Information (HIDDEN)This field is hidden when viewing the formCourse Name (HIDDEN)This field is hidden when viewing the formRetake Code (HIDDEN)This field is hidden when viewing the formQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/)This field is hidden when viewing the formCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
